Confronto Tra Radiomica e i Criteri Convenzionali di Risposta Nella Previsione Della Progressione Del Tumore Desmoide Dopo Crioablazione

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Desmoid tumors (DT) are uncommon tumors that arise from musculoaponeurotic structures. Despite benign, they can cause pain and disability due to their tendency to be locally aggressive. Cryoablation, a technique used in interventional radiology, has gained popularity in recent years as a treatment option for sporadic DT. This involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors.Although changes in the heterogeneity of tumors are commonly known, they are often ignored in response criteria that only evaluate tumor size in a single dimension, such as Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Nevertheless, MRI can reveal early changes in tumor heterogeneity in responding tumors, resulting from a reduction in cellular area and an increase in fibro-necrotic content, before any dimensional changes occur. These changes in heterogeneity can be quantified using a radiomics approach. The aim of this study is to develop radiomics response criteria dedicated to the evaluation of DT treated with cryoablation as a first line treatment and to compare their performance with those of alternative radiologic response criteria for predicting progression according to RECIST 1.1.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• desmoid tumor treated at Rizzoli Orthopaedic Institute with cryoablation

• baseline MRI

• clinical and radiologic follow-up until disease progression or the start of a new line of treatment performed every 3 months, with a minimum of 6 months follow-up

Locations
Other Locations
Italy
Giancarlo Facchini
RECRUITING
Bologna
Time Frame
Start Date: 2024-02-20
Estimated Completion Date: 2026-10-31
Participants
Target number of participants: 21
Treatments
Performed cryotherapy
Patients who received cryoablation for desmoid tumor and no chemotherapy
Related Therapeutic Areas
Sponsors
Leads: Istituto Ortopedico Rizzoli
Collaborators: University of Sao Paulo

This content was sourced from clinicaltrials.gov